Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol
Study context
- Population
- People with T1D on MDI, plus an exploratory cohort of people with T2D on MDIT1D n = 278
- Planned comparison
- MELISSA system vs usual care
- Primary endpoint
- Between-group change in % time in target range (3.9-10.0 mmol/L [70-180 mg/dL])
- Follow-up
- Baseline to study end
Methodological details22-week, European multicentre, prospective, open-label, blinded endpoint
- 22-week
- European multicentre
- Prospective
- Open-label
- Blinded endpoint
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol. Diabetes Obes Metab. Published 19 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →